Uncategorized
FDA gives greenlight for phase 2 study of travoprost with iDose delivery system
The FDA will allow Glaukos to initiate a U.S. investigational new drug phase 2 study of a travoprost intraocular implant with the iDose delivery system in patients with glaucoma, according to a press release. “We are very pleased that the FDA is allowing this trial to begin several months in advance of our original target date,” Thomas Burns, president and CEO of Glaukos, said in the release.